Exicure, Inc. (XCUR): Total Assets
$14.04M
As of 2025-12-31
$11.40M
As of 2026-06-30
-15.6%
3-year compound annual growth
-32.5%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.04M | -6.7% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $15.06M | +30.0% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $11.58M | -50.4% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $23.33M | -64.0% | 2024-06-06, Balance as of period end |
| 2021-12-31 | $64.87M | -35.4% | 2023-03-27, Balance as of period end |
| 2020-12-31 | $100.44M | -12.9% | 2022-03-25, Balance as of period end |
| 2019-12-31 | $115.26M | +300.8% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $28.76M | -0.8% | 2020-03-10, Balance as of period end |
| 2017-12-31 | $28.99M | n/c | 2019-09-23, Balance as of period end |
| 2016-12-31 | $20.58M | n/a | 2018-03-09, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Exicure, Inc. (XCUR) | 2025-12-31 | $14.04M | -6.7% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare XCUR, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗